H3N2感染(H3N2 Infection):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:H3N2 Infection - Pipeline Review, H1 2015
◆商品コード:GMDHC6284IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年2月24日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるH3N2感染(H3N2 Infection)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・H3N2感染(H3N2 Infection)の概要
・H3N2感染(H3N2 Infection)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・H3N2感染(H3N2 Infection)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・H3N2感染(H3N2 Infection)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・H3N2感染(H3N2 Infection)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

H3N2 Infection – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘H3N2 Infection – Pipeline Review, H1 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
H3N2 Infection Overview 7
Therapeutics Development 8
Pipeline Products for H3N2 Infection – Overview 8
Pipeline Products for H3N2 Infection – Comparative Analysis 9
H3N2 Infection – Therapeutics under Development by Companies 10
H3N2 Infection – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
H3N2 Infection – Products under Development by Companies 14
H3N2 Infection – Companies Involved in Therapeutics Development 15
AlphaVax, Inc. 15
Colby Pharmaceutical Company 16
Crucell N.V. 17
Cure Lab, Inc. 18
Inovio Pharmaceuticals, Inc. 19
Johnson & Johnson 20
NanoViricides, Inc. 21
REPLICor Inc. 22
Takeda Pharmaceutical Company Limited 23
Vaxart, Inc. 24
H3N2 Infection – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Aspidasept – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AVX-502 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bordetella pertussis [strain BPZE1] vaccine – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C-05 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CLVax-1.0 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CR-9114 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Gamma-Flu – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ID-38 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
influenza [H3N2] vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
influenza vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
JVRS-100 + influenza [H1N1/H3N2] vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NVINF-1 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NVINF-2 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REP-9 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
seasonal influenza [H3N2] vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VX-787 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
H3N2 Infection – Recent Pipeline Updates 53
H3N2 Infection – Dormant Projects 59
H3N2 Infection – Product Development Milestones 60
Featured News & Press Releases 60
Oct 09, 2012: NanoViricides’s Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

[List of Tables]
Number of Products under Development for H3N2 Infection, H1 2015 8
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
H3N2 Infection - Pipeline by AlphaVax, Inc., H1 2015 15
H3N2 Infection - Pipeline by Colby Pharmaceutical Company, H1 2015 16
H3N2 Infection - Pipeline by Crucell N.V., H1 2015 17
H3N2 Infection - Pipeline by Cure Lab, Inc., H1 2015 18
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 19
H3N2 Infection - Pipeline by Johnson & Johnson, H1 2015 20
H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2015 21
H3N2 Infection - Pipeline by REPLICor Inc., H1 2015 22
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23
H3N2 Infection - Pipeline by Vaxart, Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Assessment by Combination Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2015 53
H3N2 Infection - Dormant Projects, H1 2015 59

[List of Figures]
Number of Products under Development for H3N2 Infection, H1 2015 8
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 28
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

【掲載企業】

AlphaVax, Inc.
Colby Pharmaceutical Company
Crucell N.V.
Cure Lab, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
NanoViricides, Inc.
REPLICor Inc.
Takeda Pharmaceutical Company Limited
Vaxart, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[H3N2感染(H3N2 Infection):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆